Teva to expand into long-acting Schizophrenia injectable medication - LifeSci Voice
Teva: Er der endelig lys forude? - ProInvestor
Kåre Schultz venter at stoppe i Teva i 2023 — MedWatch
Ex-pharmaceutical company boss faces insider trading charges over Teva deal | The Times of Israel
Kåre Schultz er tavs om mulig kontraktforlængelse: “Det skaber bare unødvendige rygter”
Teva CEO Schultz took a big pay cut last year—but he bagged a contract extension, too | Fierce Pharma
Kåre Schultz forlænger kontrakt med Teva — MedWatch
Cureatr to Be Named Top Place to Work for Work Flexibility and Vacation and Time off in Muse Vibe Awards 2022
Teva indgår milliardforlig i opiodsag — MedWatch
Teva CORE | Comprehensive Oncology Reimbursement Expertise
Teva takes 2nd long-acting schizophrenia drug into phase 3
Vigtig godkendelse i hus - medicinalkæmpe er blevet 57 mia. kr. mere værd under Kåre Schultz
Teva to expand into long-acting Schizophrenia injectable medication - LifeSci Voice
Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis® in the United States | Business Wire
Kåre Schultz forlænger med Teva: Får op til 26 mio. kr. mere i løn
Kåre Schultz forlænger kontrakt med Teva — MedWatch
Teva CORE | Comprehensive Oncology Reimbursement Expertise
Teva takes 2nd long-acting schizophrenia drug into phase 3
Now That Teva Has Stabilized, Teva Stock Looks Undervalued | InvestorPlace
Teva USA
Teva taps new CFO, hikes legal set-aside to more than $1B as opioid deal falters | Fierce Pharma
Business-update: Kåre Schultz forgyldt med lønforhøjelse på op til 26 mio. kroner
